The aim of the paper was to study the therapeutic effect of a new drug, leukinferon for injections, representing a complex of IF-alpha (10 000 I. U.) and cytokins, in patients with atopic dermatitis. Leukinferon injections (i. m.) were paralleled by combined therapy; two injections per week were administered, 6-10 injections per course. Leukinferon therapy resulted in a manifest clinical improvement and in positive shifts in the immune status of patients: a trend to normalization of the counts of B cells, theophylline-resistant and theophylline-sensitive T lymphocytes was observed.